دورية أكاديمية
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab.
| العنوان: | Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamab. |
|---|---|
| المؤلفون: | Willemin ME; Janssen Research & Development, Beerse, Belgium., Wang Lin SX; Janssen Research & Development, Spring House, Pennsylvania, USA., De Zwart L; Janssen Research & Development, Beerse, Belgium., Wu LS; Janssen Research & Development, South San Francisco, California, USA., Miao X; Janssen Research & Development, Spring House, Pennsylvania, USA., Verona R; Janssen Research & Development, Spring House, Pennsylvania, USA., Banerjee A; Janssen Research & Development, Spring House, Pennsylvania, USA., Liu B; Janssen Research & Development, Raritan, New Jersey, USA., Kobos R; Janssen Research & Development, Raritan, New Jersey, USA., Qi M; Janssen Research & Development, Raritan, New Jersey, USA., Ouellet D; Janssen Research & Development, Spring House, Pennsylvania, USA., Goldberg JD; Janssen Research & Development, Raritan, New Jersey, USA., Girgis S; Janssen Research & Development, Spring House, Pennsylvania, USA. |
| المصدر: | CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jul; Vol. 13 (7), pp. 1117-1129. Date of Electronic Publication: 2024 Jun 03. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Hoboken, NJ : Wiley Original Publication: New York, NY : Nature Pub. Group |
| مواضيع طبية MeSH: | Drug Interactions* , Interleukin-6*/blood , Cytokine Release Syndrome*/drug therapy , Models, Biological*, Humans ; Cytochrome P-450 Enzyme System/metabolism ; Area Under Curve ; Cyclosporine/pharmacokinetics ; Cyclosporine/administration & dosage ; Midazolam/pharmacokinetics ; Midazolam/administration & dosage ; Omeprazole/pharmacokinetics ; Omeprazole/administration & dosage ; Simvastatin/pharmacokinetics ; Simvastatin/administration & dosage |
| مستخلص: | Cytokine release syndrome (CRS) was associated with teclistamab treatment in the phase I/II MajesTEC-1 study. Cytokines, especially interleukin (IL)-6, are known suppressors of cytochrome P450 (CYP) enzymes' activity. A physiologically based pharmacokinetic model evaluated the impact of IL-6 serum levels on exposure of substrates of various CYP enzymes (1A2, 2C9, 2C19, 3A4, 3A5). Two IL-6 kinetics profiles were assessed, the mean IL-6 profile with a maximum concentration (C (© 2024 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.) |
| References: | Clin Pharmacokinet. 2010 May;49(5):295-310. (PMID: 20384392) Clin Pharmacol Ther. 2009 Jul;86(1):54-61. (PMID: 19369937) Drug Metab Dispos. 2022 Oct;50(10):1322-1331. (PMID: 36100353) Clin Pharmacol Ther. 2022 Mar;111(3):579-584. (PMID: 34496043) Eur J Clin Pharmacol. 2004 May;60(3):165-71. (PMID: 15045499) Blood. 2011 May 5;117(18):4691-5. (PMID: 21292775) Am J Hematol. 2020 May;95(5):548-567. (PMID: 32212178) J Card Fail. 2002 Oct;8(5):315-9. (PMID: 12411982) Biosensors (Basel). 2022 Sep 14;12(9):. (PMID: 36140141) Curr Drug Metab. 2012 Sep 1;13(7):923-9. (PMID: 22475265) CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):822-832. (PMID: 35445542) Clin Pharmacol Ther. 2011 May;89(5):735-40. (PMID: 21430660) Blood. 2014 Jul 10;124(2):188-95. (PMID: 24876563) CPT Pharmacometrics Syst Pharmacol. 2024 Mar;13(3):396-409. (PMID: 38044486) CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):234-246. (PMID: 38050329) Drug Metab Dispos. 2011 Feb;39(2):170-3. (PMID: 21036951) CPT Pharmacometrics Syst Pharmacol. 2024 Jul;13(7):1117-1129. (PMID: 38831634) N Engl J Med. 2022 Aug 11;387(6):495-505. (PMID: 35661166) Clin Pharmacol Ther. 2013 Aug;94(2):260-8. (PMID: 23588308) Blood Adv. 2020 Sep 22;4(18):4538-4549. (PMID: 32956453) Clin Pharmacol Ther. 2023 Jun;113(6):1185-1198. (PMID: 36477720) CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):30-43. (PMID: 34791831) Clin Transl Sci. 2023 Jun;16(6):922-936. (PMID: 36890677) J Clin Pharmacol. 2015 Dec;55(12):1386-94. (PMID: 26054042) Biochem Pharmacol. 1999 Apr 15;57(8):951-4. (PMID: 10086330) Lancet. 2021 Aug 21;398(10301):665-674. (PMID: 34388396) Drug Metab Dispos. 2013 Sep;41(9):1598-609. (PMID: 23792813) Drug Metab Dispos. 2011 Aug;39(8):1415-22. (PMID: 21555507) J Pharmacol Exp Ther. 1994 Jan;268(1):515-21. (PMID: 8301593) Pharmaceuticals (Basel). 2022 Apr 22;15(5):. (PMID: 35631335) AAPS J. 2016 May;18(3):767-76. (PMID: 26961818) Br J Clin Pharmacol. 2016 Jul;82(1):160-7. (PMID: 26991517) Clin Pharmacol Ther. 2015 Mar;97(3):247-62. (PMID: 25670209) Clin Transl Sci. 2022 Feb;15(2):464-476. (PMID: 34581012) Pharmacogenetics. 2002 Mar;12(2):101-9. (PMID: 11875364) Drug Metab Pharmacokinet. 2010;25(4):367-78. (PMID: 20814158) AAPS J. 2019 Mar 18;21(3):42. (PMID: 30887238) CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):507-15. (PMID: 26451330) |
| معلومات مُعتمدة: | Janssen Research & Development, LLC |
| المشرفين على المادة: | 0 (Interleukin-6) 9035-51-2 (Cytochrome P-450 Enzyme System) 83HN0GTJ6D (Cyclosporine) R60L0SM5BC (Midazolam) KG60484QX9 (Omeprazole) AGG2FN16EV (Simvastatin) |
| تواريخ الأحداث: | Date Created: 20240604 Date Completed: 20240715 Latest Revision: 20240717 |
| رمز التحديث: | 20240717 |
| مُعرف محوري في PubMed: | PMC11247108 |
| DOI: | 10.1002/psp4.13144 |
| PMID: | 38831634 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2163-8306 |
|---|---|
| DOI: | 10.1002/psp4.13144 |